Rule 8.3- Neuropharm Group plc
21 November 2009 - 12:15AM
UK Regulatory
TIDMLLOY TIDMNPH
RNS Number : 8607C
Lloyds Banking Group PLC
20 November 2009
FORM 8.3
DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE
(Rule 8.3 of the Takeover Code)
1. KEY INFORMATION
+--------------------------------------+--------------------------------------------+
| Name of person dealing (Note 1) | Lloyds Banking Group plc and its |
| | subsidiaries |
| | |
+--------------------------------------+--------------------------------------------+
| Company dealt in | Neuropharm Group plc |
| | |
+--------------------------------------+--------------------------------------------+
| Class of relevant security to which | Ordinary 10p |
| the dealings being disclosed | |
| relate (Note 2) | |
| | |
+--------------------------------------+--------------------------------------------+
| Date of dealing | 19 November 2009 |
+--------------------------------------+--------------------------------------------+
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of relevant
security dealt in (Note 3)
+--------------------------------+-----------+----------+--------+---------+
| | Long | | Short | |
+--------------------------------+-----------+----------+--------+---------+
| | Number | (%) | Number | (%) |
+--------------------------------+-----------+----------+--------+---------+
| (1) Relevant securities | 3,033,071 | (9.618%) | | |
+--------------------------------+-----------+----------+--------+---------+
| (2) Derivatives (other than | | | | |
| options) | | | | |
+--------------------------------+-----------+----------+--------+---------+
| (3) Options and agreements to | | | | |
| purchase/sell | | | | |
+--------------------------------+-----------+----------+--------+---------+
| Total | 3,033,071 | (9.618%) | | |
+--------------------------------+-----------+----------+--------+---------+
(b) Interests and short positions in relevant securities of the company, other
than the class dealt in (Note 3)
+--------------------------------+----------+--------+--------+-----+
| Class of relevant security: | Long | | Short | |
+--------------------------------+----------+--------+--------+-----+
| | Number | (%) | Number | (%) |
+--------------------------------+----------+--------+--------+-----+
| (1) Relevant securities | | | | |
+--------------------------------+----------+--------+--------+-----+
| (2) Derivatives (other than | | | | |
| options) | | | | |
+--------------------------------+----------+--------+--------+-----+
| (3) Options and agreements to | | | | |
| purchase/sell | | | | |
+--------------------------------+----------+--------+--------+-----+
| Total | | | | |
+--------------------------------+----------+--------+--------+-----+
(c) Rights to subscribe (Note 3)
+------------------------+----------------------------------+
| Class of relevant | Details |
| security: | |
+------------------------+----------------------------------+
| | |
+------------------------+----------------------------------+
3. DEALINGS (Note 4)
(a) Purchases and sales
+------------------------------+---------------------------+---------------+
| Purchase/sale | Number of securities | Price per |
| | | unit (Note 5) |
+------------------------------+---------------------------+---------------+
| Sale | 400 | GBP0.150 |
+------------------------------+---------------------------+---------------+
| | | |
+------------------------------+---------------------------+---------------+
| | | |
+------------------------------+---------------------------+---------------+
| | | |
+------------------------------+---------------------------+---------------+
(b) Derivatives transactions (other than options)
+------------+------------+-----------------+--------------+
| Product | Long/short | Number of | Price per |
| name, e.g. | (Note 6) | securities | unit (Note |
| CFD | | (Note 7) | 5) |
| | | | |
+------------+------------+-----------------+--------------+
| | | | |
+------------+------------+-----------------+--------------+
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
+-----------+-------------+------------+----------+-----------+--------+---------------+
| Product | Writing, | Number | Exercise | Type, | Expiry | Option |
| name,e.g. | selling, | of | price | e.g. | date | money |
| call | purchasing, | securities | | American, | | paid/received |
| option | varying | to which | | European | | per unit |
| | etc. | the option | | etc. | | (Note 5) |
| | | relates | | | | |
| | | (Note 7) | | | | |
+-----------+-------------+------------+----------+-----------+--------+---------------+
| | | | | | | |
+-----------+-------------+------------+----------+-----------+--------+---------------+
(ii) Exercising
+--------------+------------------+-------------------------+
| Product | Number of | Exercise price per unit |
| name, e.g. | securities | (Note 5) |
| call option | | |
+--------------+------------------+-------------------------+
| | | |
+--------------+------------------+-------------------------+
(d) Other dealings (including new securities) (Note 4)
+------------------------+---------------+-------------------+
| Nature of transaction | Details | Price per unit |
| (Note 8) | | (if |
| | | applicable) (Note |
| | | 5) |
+------------------------+---------------+-------------------+
| | | |
+------------------------+---------------+-------------------+
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced. If none, this should be
stated.
..............................................................................
N/A
..............................................................................
Is a Supplemental Form 8 attached? (Note 9)NO
+------------------------------------+---------------------+
| Date of disclosure | 20 November 2009 |
| | |
+------------------------------------+---------------------+
| Contact name | Matthew Wilson |
| | |
+------------------------------------+---------------------+
| Telephone number | 0113 235 7729 |
| | |
+------------------------------------+---------------------+
| If a connected EFM, name of | |
| offeree/offeror with which | |
| connected | |
| | |
+------------------------------------+---------------------+
| If a connected EFM, state nature | |
| of connection (Note 10) | |
| | |
+------------------------------------+---------------------+
Notes
The Notes on Form 8.3 can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
RETBMBJTMMBTBIL
Neuropharm (LSE:NPH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Neuropharm (LSE:NPH)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Neuropharm (London Stock Exchange): 0 recent articles
More Neuropharm News Articles